{
  "ticker": "ILA",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02967691",
  "id": "02967691",
  "pages": 18,
  "price_sensitive": false,
  "date": "20250709",
  "time": "0922",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250709/pdf/06lmnjf0w2f7pv.pdf",
  "summary": "This appears to be a corporate presentation rather than a material ASX announcement. However, key capital markets-relevant information can be extracted:\n\n**Capital & Corporate Structure**  \n- Share price (7 July 2025): **A$0.145**  \n- Market cap: **A$34.24m**  \n- Shares outstanding: **236.1m**  \n- Cash balance (31 March 2024): **A$4.82m** (excludes subsequent A$3.6m May 2025 raise)  \n\n**Strategic Transaction**  \n- Acquired **galidesivir antiviral program** from BioCryst Pharmaceuticals:  \n  - **Upfront cost**: US$550k  \n  - **Milestones**: US$500k (Phase 2 completion), US$1m (FDA approval), + tiered royalties (5-10%)  \n  - Potential **Priority Review Voucher (PRV)** worth ~A$225m  \n\n**Catalysts**  \n- Targeting **NDA submission for Marburg virus** within 12 months under FDA Animal Rule pathway  \n- Plans to initiate **non-human primate studies**  \n\nNo material trading or immediate capital-raising actions identified in this presentation.",
  "usage": {
    "prompt_tokens": 4517,
    "completion_tokens": 249,
    "total_tokens": 4766,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-08T23:54:44.695139"
}